Kliniken Essen-Mitte

Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R (2024) Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, et al. Journal article Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer (2024) Gaß P, Thiel FC, Häberle L, Ackermann S, Theuser AK, Hummel N, Boehm S, et al. Journal article Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer (2024) Fasching P, Decker T, Hartkopf A, Nusch A, Heinrich BJ, Kurbacher C, Fuchs R, et al. Journal article Survey on the working, training, and research conditions of resident physicians in internistic and rheumatological continuing education-BEWUSST. (2024) Proft F, Vossen D, Baraliakos X, Berliner MN, Fleck M, Keyßer G, Krause A, et al. Journal article Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 (2024) Pusztai L, Denkert C, O'Shaughnessy J, Cortes J, Dent R, McArthur H, Kümmel S, et al. Journal article Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease (2024) Dotsenko V, Tewes B, Hils M, Pasternack R, Isola J, Taavela J, Popp A, et al. Journal article Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial (2023) Lorusso D, Mouret-Reynier MA, Harter P, Cropet C, Caballero C, Wolfrum-Ristau P, Satoh T, et al. Journal article PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant (2023) Degenhardt T, Fasching P, Lüftner D, Müller V, Thomssen C, Schem C, Witzel I, et al. Journal article Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy (2023) Huober J, van Mackelenbergh M, Schneeweiss A, Seither F, Blohmer JU, Denkert C, Tesch H, et al. Journal article Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy (2023) Harbeck N, Kates R, Schinköthe T, Schumacher J, Wuerstlein R, Degenhardt T, Lüftner D, et al. Journal article, Review article